Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

A clinical pharmacy-oriented drug surveillance network: I. Program description.

T H Grasela¹, J J Schentag

¹Pharmacoepidemiology Research Center, Millard Fillmore Hospital; Buffalo, NY 14209.

Drug Intelligence & Clinical Pharmacy

|November 1, 1987

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The paradox of scientific excellence and the search for productivity in pharmaceutical research and development.

Clinical pharmacology and therapeutics·2014

Same author

Improving productivity with model-based drug development: an enterprise perspective.

Clinical pharmacology and therapeutics·2010

Same author

Impact of organism species on microbial eradication and development of resistance in severe gram-negative pneumonia.

Journal of chemotherapy (Florence, Italy)·2010

Same author

A case series of macrolide treatment failures in community acquired pneumonia.

Journal of chemotherapy (Florence, Italy)·2007

Same author

Pharmacometrics and the transition to model-based development.

Clinical pharmacology and therapeutics·2007

Same author

Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy.

Current opinion in infectious diseases·2006

Same journal

Profile of prescription medication in a pediatric population.

Drug intelligence & clinical pharmacy·1988

Same journal

SI units in drug therapeutics.

Drug intelligence & clinical pharmacy·1988

Same journal

Physicians' review of significant interventions by clinical pharmacists in inpatient care.

Drug intelligence & clinical pharmacy·1988

Same journal

Possible interaction of ranitidine with phenytoin.

Drug intelligence & clinical pharmacy·1988

Same journal

Famotidine-associated mental confusion in elderly patients.

Drug intelligence & clinical pharmacy·1988

Same journal

Intravenous self-administration of elemental mercury: efficacy of dimercaprol therapy.

Drug intelligence & clinical pharmacy·1988

See all related articles

A nationwide network of clinical pharmacists enhances postmarketing drug surveillance. This approach identifies potential drug safety issues and effectiveness in real-world patient populations.

Area of Science:

Pharmacovigilance
Drug Safety Monitoring
Clinical Pharmacy Practice

Background:

New drug development has limitations in evaluating long-term safety.
Existing postmarketing surveillance systems have significant limitations.
There is a need for innovative approaches to identify rare adverse drug reactions.

Purpose of the Study:

To establish a nationwide network of clinical pharmacists for postmarketing drug surveillance.
To rapidly identify potential drug safety problems and assess drug effectiveness.
To support studies on multiple drugs and disease states in large patient populations.

Main Methods:

Organized a nationwide network of 383 clinical pharmacists across all 50 states.
Utilized standardized data collection forms for concurrent monitoring.

Related Experiment Videos

Collected data on drug therapy outcomes in targeted inpatient, nursing home, and ambulatory care settings.

Main Results:

The network monitors over 150,000 inpatient beds, 40,000 nursing home beds, and 800,000 ambulatory care visits annually.
Clinical pharmacists actively monitor drug safety and effectiveness in real-world settings.
Data analysis provides clinically relevant information on drug therapy outcomes.

Conclusions:

A clinical pharmacist network offers an innovative solution for postmarketing drug surveillance.
This approach enables the identification of uncommon adverse drug reactions.
The system yields valuable insights into drug efficacy and safety under actual clinical conditions.